Giardia lamblia infection
Methodology & AI Transparency ⓘ
Giardia lamblia infection Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Clinical triage of Giardia lamblia infection (A07.1) in Infections & Antivirals relies on rapid antigen/NAAT PCR in Giardia lamblia infection (A07.1: diagnostics), guiding step-wise therapeutic adjustments toward C-Reactive Protein / in Giardia lamblia infection (A07.1: Procalcitonin) (Resolution to baseline (A07.1)).
- 2 Real-world patient consensus: Diagnostic registry A07.1: Giardia lamblia infection is managed within Infections & Antivirals.
- 3 Typical cash cost range: Primary evaluation for Giardia lamblia infection incorporates rapid antigen/NAAT PCR in Giardia lamblia infection (A07.1: diagnostics) and symptom diary review.
- 4 Top reported side effects / signs: Objective lab/clinical target for Giardia lamblia infection: Complete Blood Count in Giardia lamblia infection (A07.1: (WBC & Differential)) (WBC 4.0 – 10.0 x10^3/uL (A07.1)) and C-Reactive Protein / in Giardia lamblia infection (A07.1: Procalcitonin).
Ask our AI Specialists anything about Giardia lamblia infection
What Is Giardia lamblia infection?
Clinical triage of Giardia lamblia infection (A07.1) in Infections & Antivirals relies on rapid antigen/NAAT PCR in Giardia lamblia infection (A07.1: diagnostics), guiding step-wise therapeutic adjustments toward C-Reactive Protein / in Giardia lamblia infection (A07.1: Procalcitonin) (Resolution to baseline (A07.1)).
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in infections & antivirals, Giardia lamblia infection (A07.1) involves tissue neutrophil/lymphocyte recruitment [Giardia lamblia infection A07.1]. progression correlates with shifts in Complete Blood Count in Giardia lamblia infection (A07.1: (WBC & Differential)) (WBC 4.0 – 10.0 x10^3/uL (A07.1)).
Common Symptoms & Clinical Signs
- • Presentation of Giardia lamblia infection (A07.1): sore throat, productive in Giardia lamblia infection (A07.1: cough, sinus/ear pain,)
- • Secondary Giardia lamblia infection clinical sign: painful vesicular rash in Giardia lamblia infection (A07.1: in a dermatomal)
- • Symptom flares in Giardia lamblia infection correlating with Complete Blood Count in Giardia lamblia infection (A07.1: (WBC & Differential)) deviation outside WBC 4.0 – 10.0 x10^3/uL (A07.1)
- • Functional infections & antivirals impact requiring rapid antigen/NAAT PCR in Giardia lamblia infection (A07.1: diagnostics) evaluation (A07.1)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Giardia lamblia infection Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | A07.1 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Bacterial, Viral & Fungal Infections | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Complete Blood Count in Giardia lamblia infection (A07.1: (WBC & Differential)) | WBC 4.0 – 10.0 x10^3/uL (A07.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: C-Reactive Protein / in Giardia lamblia infection (A07.1: Procalcitonin) | Resolution to baseline (A07.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Targeted PCR / in Giardia lamblia infection (A07.1: Culture & Sensitivity) | Pathogen clearance / negative test (A07.1) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Giardia lamblia infection
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Nitazoxanide Alinia • RxCUI 427163 | Antiprotozoal | 83% | $80.0125 | $ 2069.25 /mo |
| Giar Homo (Giardia Lamblia, Giardia Lamblia DNA) Giar Homo • RxCUI RXN-B437422187 | Over-the-Counter Clinical Monograph | 76% | $3.2500 | $ 242.50 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Giardia lamblia infection)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Microbiome and Metabolome Restoration After Administration of Fecal Microbiota, Clinical response and RBL administration were associated with significant restoration of microbiota and BA composition. The Journal of infectious diseases • 2025-07-11 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39172632 ↗ |
| New Insights on Safety and Effectiveness From the Cabotegravir and Rilpivirine Implementation: What a 373-Participant Study Found CAB + RPV LA Q2M was well tolerated and highly effective in maintaining virologic suppression with a low rate of virologic failure. Journal of acquired immune deficiency syndromes (1999) • 2024-08-15 • Phase III Randomized Trial | N = 373 | 87/100 | PMID 38985445 ↗ |
| Can This Approach Help? Inside the Latest Research on Efficacy, Safety, and how the body absorbs the medicine by Body Mass Index CAB + RPV LA was efficacious and well tolerated, regardless of baseline BMI category. The Journal of infectious diseases • 2024-07-25 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 39052748 ↗ |
Giardia lamblia infection Patient Community & “People Like Me” Threads
Filter Giardia lamblia infection community threads and patient logs by age, biological sex, dosage, and treatment duration.